EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis

Angelo Massimiliano D'Erme, Cristian Fidanzi, Matteo Bevilacqua, Thomas Bieber, Cristina Tuoni, Aldo Paolicchi, Maria Franzini, Riccardo Morganti, Francesca Papadia, Agata Janowska, Valentina Dini, Marco Romanelli

JAMA Dermatology · 2024

DOI: 10.1001/jamadermatol.2024.3178 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Angelo Massimiliano D'Erme und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Chemokine CCL17, Biomarkers, Fetal Blood. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Atopic dermatitis (AD) is the most prevalent chronic skin condition characterized by inflammation and itching. Currently, there is no reliable method for identifying which newborns might have an increased risk of developing AD.

Objective

To evaluate the predictive value of serological biomarkers, such as CCL17/thymus- and activation-regulated chemokine, CCL18, CCL22, CCL27, IL-31, and thymus stromal lymphopoietin, with transepidermal water loss (TEWL) and hydration rate and the development of AD in infants. Design, Setting, and Participants This observational prospective study included 40 consecutive full-term newborns from a single university hospital in Pisa, Italy. The cutaneous markers of infants were assessed at 1, 6, and 12 months of age, while the biomarkers from the 10-mL sample of cord blood taken at birth were measured after delivery. Data were collected from March to December 2018 and analyzed from January to April 2019. Main Outcomes and Measures Level of serological biomarkers associated with TEWL and hydration rate, as well as the emergence of AD during the first 12 months of life.

Results

All 40 included infants (27 male [68%]) completed the study. At 6 months, 16 infants presented symptoms and signs of AD (AD group) and 24 did not (non-AD group). Infants with AD signs had statistically significant anterior cubital fossa TEWL values at 1, 6, and 12 months of age compared to those without AD signs. No statistically significant correlations were observed between the TEWL measured at the anterior part of knee and hydration rate at the anterior cubital fossa at first month in the 2 groups. With regard to the blood biomarkers, at birth those in the AD group vs the non-AD group had statistically significant higher levels of CCL17/thymus- and activation-regulated chemokine (median [IQR], 716 [509-951] pg/mL vs 419 [24-566] pg/mL; P = .003) and IL-31 (median [IQR], 212 [114-409] pg/mL vs 97 [52-277] pg/mL; P = .04); in contrast, no statistically significant serum level differences were registered for thymus stromal lymphopoietin (median [IQR], 105 [66-295] pg/mL vs 88 [43-187] pg/mL), CCL18 (median [IQR], 1236 [1115-1605] pg/mL vs 1255 [1188-1677] pg/mL), CCL22 (median [IQR], 1032 [936-1454] pg/mL vs 1096 [932-1536] pg/mL), and CCL27 (median [IQR], 172 [122-251] pg/mL vs 120 [90-265] pg/mL). Conclusions and Relevance In this observational study, the analysis of TEWL at the anterior cubital fossa area occurred prior to and correlated with the clinical signs of AD. Quantification of cytokines indicated that assessing cord blood serum levels of CCL17 and IL-31 could offer new perspectives in identifying newborns who might be susceptible to AD. Larger studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicChemokine CCL17BiomarkersFetal BloodInterleukinsHumansMaleFemaleProspective StudiesInfant, NewbornInfantWater Loss, InsensiblePredictive Value of TestsCytokines

Substanzen

Chemokine CCL17BiomarkersCCL17 protein, humanInterleukinsIL31 protein, humanCytokines

Autor:innen und Institutionen

  • Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy.
  • Unit of Dermatology, Hospital of Livorno, Livorno, Italy.
  • Unit of Dermatology, Hospital of Carrara, Carrara, Italy.
  • Medicine Campus, Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
  • Division of Neonatology and NICU, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Zitieren

APA

D'Erme, A. M., Fidanzi, C., Bevilacqua, M., Bieber, T., Tuoni, C., Paolicchi, A., Franzini, M., Morganti, R., Papadia, F., Janowska, A., Dini, V., & Romanelli, M. (2024). Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.3178

Vancouver

D'Erme AM, Fidanzi C, Bevilacqua M, Bieber T, Tuoni C, Paolicchi A, et al. Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.3178

BibTeX
@article{DErme2024,
  author = {D'Erme, Angelo Massimiliano and Fidanzi, Cristian and Bevilacqua, Matteo and Bieber, Thomas and Tuoni, Cristina and Paolicchi, Aldo and Franzini, Maria and Morganti, Riccardo and Papadia, Francesca and Janowska, Agata and Dini, Valentina and Romanelli, Marco},
  title = {Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis},
  journal = {JAMA Dermatology},
  year = {2024},
  doi = {10.1001/jamadermatol.2024.3178}
}
Kostenlos starten →